Business
VVT Med Signs $3.7 Million Distribution Agreement in India, Achieves European Sales Milestone and Announces Proposed Debt Settlement
VVT Med Signs $3.7 Million Distribution Agreement in India, Achieves European Sales Milestone and...
About this update from Vvt Med Inc.
[{"type":"text","content":"\n\n\nVVT Med Signs $3.7 Million Distribution Agreement in India, Achieves European Sales Milestone and Announces Proposed Debt Settlement\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\nVANCOUVER, BC, Nov. 11, 2025 /CNW/ - VVT Med Inc. (TSXV: VVTM) (\"VVT Med\" or the \"Company\"), a leader in next-generation, minimally invasive, non-thermal, and non-tumescent (\"NT-NT\") solutions for venous disease, is pleased to announce several milestones in the execution of its stated global expansion, sales and capital strategies.\n$3.7 Million Distribution Agreement in India\nVVT Med has entered into a five-year distribution agreement dated September 5, 2025 with Medworks India, a leading healthcare distributor in India, for its ScleroSafe™ medical device in the varicose vein treatment market (the \"Distribution Agreement\").\nThe Distribution Agreement commits Medworks India to purchase CAD $3.7 million worth of ScleroSafe™ units over a five-year period, with CAD $1.85 million under a \"Buy & Pay\" model, subject to the early termination of the Distribution Agreement. The Company's ScleroSafe™ received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) under Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India in 2022.\nThe Distribution Agreement will be in effect for five years from the effective date, unless terminated earlier or extended through a written mutual amendment. The Company may terminate the agreement for cause, including payment defaults, failure to meet obligations or sales targets, legal changes, IP disputes, or certain organizational changes within Medworks India. Either party may also terminate the agreement for convenience with 30 days' notice.\nFollowing several dozen successful procedures performed across key vein centers, physician satisfaction has been high, resulting in confirmed reorders. Medworks has already placed its initial stocking order, marking the beginning of commercial rollout and physician adoption across India\n\"This par...